A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Clinical trial NCT06311721 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06311721
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-09
- Primary completion
- 2028-01-10
- Enrollment
- 315
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.